BICO Group Valuation
Is BICO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BICO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate BICO's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BICO's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BICO?
Key metric: As BICO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is BICO's PS Ratio? | |
|---|---|
| PS Ratio | 1.1x |
| Sales | SEK 2.42b |
| Market Cap | SEK 2.57b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.6x |
| Enterprise Value/EBITDA | 53.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BICO's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 6.9x | ||
GENO Genovis AB (publ.) | 14.1x | 10.1% | SEK 1.8b |
MCAP MedCap | 4.6x | 13.2% | SEK 8.3b |
MAGLE Magle Chemoswed Holding | 2.9x | 27.0% | SEK 599.9m |
BIOT Biotage | 5.9x | 12.1% | SEK 12.4b |
BICO BICO Group | 1.1x | 8.3% | SEK 2.6b |
Price-To-Sales vs Peers: BICO is good value based on its Price-To-Sales Ratio (1.1x) compared to the peer average (6.9x).
Price to Sales Ratio vs Industry
How does BICO's PS Ratio compare vs other companies in the European Life Sciences Industry?
| 5 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: BICO is good value based on its Price-To-Sales Ratio (1.1x) compared to the European Life Sciences industry average (4.3x).
Price to Sales Ratio vs Fair Ratio
What is BICO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.1x |
| Fair PS Ratio | 2.5x |
Price-To-Sales vs Fair Ratio: BICO is good value based on its Price-To-Sales Ratio (1.1x) compared to the estimated Fair Price-To-Sales Ratio (2.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
AstraZeneca
UK£162.4b
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
AZN
UK£1,462.00
7D
5.0%
1Y
8.2%
Swedish Orphan Biovitrum
SEK 99.6b
An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.
SOBI
SEK 290.00
7D
-2.7%
1Y
14.5%
PMD Device Solutions
SEK 35.3m
A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.
PMDS
SEK 1.36
7D
-8.1%
1Y
n/a